BPC-157 vs LL-37
Extensively Studied vs Well Studied
synergistic Enhanced wound healing through complementary mechanisms.
Molecular Data
BPC-157 LL-37
Weight 1,419.53 Da —
Half-life <30 minutes Short (rapid proteolytic degradation)
Chain 15 amino acids 37 amino acids
Type Pentadecapeptide Cationic antimicrobial peptide
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
LL-37
01 Direct wound healing acceleration
02 Broad-spectrum antimicrobial activity
03 Activity against resistant bacteria (MRSA, MDRPA)
04 Enhanced tissue regeneration
05 Immune modulation
06 Local antimicrobial protection
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
LL-37
0.5-1.6 mg/mL topical gel or 100-150 mcg injectable / Topical: Daily to twice weekly on wounds. Injectable: Once daily subcutaneous
Systemic immune support 100-150mcg Once daily
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
LL-37
Generally well-tolerated
Mild injection site reactions (injectable)
Local irritation at application site (topical)
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Pre-existing hypersensitivity to peptides
Compromised immune status (relative contraindication)
Non-sterile wound environments
Research Evidence
BPC-157 LL-37
Status Extensively Studied Well Studied
References 6 studies 4 studies
Latest January 2025 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.